Australia regulator to review price hike in Covid-19 antigen tests

Australia's antitrust regulator said it has contacted suppliers of Covid-19 rapid antigen test kits to examine pricing pressures in the market

Covid-19, Australia Covid-19,
Photo: Bloomberg
Reuters
2 min read Last Updated : Jan 04 2022 | 11:16 AM IST
Australia's antitrust regulator said on Tuesday it has contacted suppliers of COVID-19 rapid antigen test kits to examine pricing pressures in the market, as calls grow louder for the government to make the tests free amid a severe shortage of the kits.

The Australian Competition and Consumer Commission (ACCC) said it will review information received from suppliers, retailers and the public to determine any potential misconduct.

Australia approved more than a dozen rapid antigen test kits and a majority of them are from China.

Hangzhou Biotest Biotech, whose rapid antigen test was approved in Australia in October, said orders for its product from the country increased significantly in December and the trend continued in early January.

"The increased demand has put some pressure on the company's production, but we still can cope with it," a Hangzhou Biotest representative told Reuters.

Last month, Prime Minister Scott Morrison sought to relieve pressure on overrun COVID-19 testing facilities and encouraged greater use of antigen tests as the spread of the Omicron variant caused a surge in cases in Australia's two most populous states.

As of Tuesday, New South Wales (NSW) and Victoria reported 37,151 new cases between them, just shy of the national one-day high of 37,212 hit a day earlier. Hospitalisations in NSW, home to Sydney, more than doubled in a week to 1,344, surpassing the record numbers hit during the Delta outbreak.

However, Morrison has said the government will not cover the cost for people to test themselves, which he put at A$15 ($10.80).

The ACCC also cautioned businesses to not collude about pricing and make any misleading claims to consumers about it.

($1 = 1.3889 Australian dollars)

(Reporting by Anushka Trivedi in Bengaluru; Additional reporting by Roxanne Liu in Beijing; Editing by Sherry Jacob-Phillips and Shounak Dasgupta)

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusAustraliaCoronavirus Tests

Next Story